Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1)provided on December 16, 2025.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
“With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer’s foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts, and continued strategic investment to maximize our opportunities for industry-leading growth at the end of the decade.”
David Denton, CFO and EVP of Pfizer:
“I’m pleased with our solid financial results in 2025. With focused commercial execution, we delivered full-year operational revenue growth of 6% for our non-COVID portfolio, and our continued financial discipline drove strong EPS performance. Today, we are reaffirming our full-year 2026 financial guidance.”
OVERALL RESULTS
Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates(4).
Results for the fourth quarter and full year of 2025 and 2024(5)are summarized below.
| ($ in millions, except per share amounts) | Fourth-Quarter | Full-Year | ||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | % Change | |||||||||
| Revenues | $ | 17,557 | $ | 17,763 | (1 | %) | $ | 62,579 | $ | 63,627 | (2 | %) | ||
| Reported(2)Net Income/(Loss) | (1,648 | ) | 410 | * | 7,771 | 8,031 | (3 | %) | ||||||
| Reported(2)Diluted EPS/(LPS) | (0.29 | ) | 0.07 | * | 1.36 | 1.41 | (3 | %) | ||||||
| Adjusted(3)Income | 3,786 | 3,592 | 5 | % | 18,406 | 17,716 | 4 | % | ||||||
| Adjusted(3)Diluted EPS | 0.66 | 0.63 | 5 | % | 3.22 | 3.11 | 4 | % | ||||||
| * Indicates calculation not meaningful or results are greater than 100%. |
REVENUES
| ($ in millions) | Fourth-Quarter | Full-Year | |||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||
| Total | Oper. | Total | Oper. | ||||||||||||||
| Global Biopharmaceuticals Business (Biopharma) | $ | 17,144 | $ | 17,413 | (2 | %) | (3 | %) | $ | 61,199 | $ | 62,400 | (2 | %) | (2 | %) | |
| Pfizer CentreOne (PC1) | 409 | 325 | 26 | % | 22 | % | 1,338 | 1,146 | 17 | % | 15 | % | |||||
| Pfizer Ignite | 4 | 26 | (83 | %) | (83 | %) | 41 | 82 | (50 | %) | (50 | %) | |||||
| TOTAL REVENUES | $ | 17,557 | $ | 17,763 | (1 | %) | (3 | %) | $ | 62,579 | $ | 63,627 | (2 | %) | (2 | %) | |
2026 FINANCIAL GUIDANCE(1)
| Revenues | $59.5 to $62.5 billion |
| Adjusted(3)SI&A Expenses | $12.5 to $13.5 billion |
| Adjusted(3)R&D Expenses | $10.5 to $11.5 billion |
| Effective Tax Rate on Adjusted(3)Income | Approximately 15.0% |
| Adjusted(3)Diluted EPS | $2.80 to $3.00 |
CAPITAL ALLOCATION
In 2025, Pfizer deployed its capital in a variety of ways, which primarily included:
Our capital allocation framework is designed to enhance long-term shareholder value, and is based on three core pillars: (i) maintaining and, over the long term, growing our dividend, (ii) reinvesting in the business, including maintaining the flexibility to deploy capital towards potential value-creating business development transactions, and (iii) in the future, the potential to resume the return of capital to shareholders through value-enhancing share repurchases. The company expects to continue to de-lever over the longer term in a prudent manner in order to maintain a balanced capital allocation strategy.
No share repurchases were completed in 2025. As of February 3, 2026, Pfizer’s remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2026.
For the fourth quarter of 2025, basic weighted-average shares outstanding of 5,686 million were used to calculate Reported(2)LPS and diluted weighted-average shares outstanding of 5,722 million were used to calculate Adjusted(3)diluted EPS.
QUARTERLY FINANCIAL HIGHLIGHTS (Fourth-Quarter 2025 vs. Fourth-Quarter 2024)
Fourth-quarter 2025 revenues totaled $17.6 billion, a decrease of $206 million, or 1%, compared to the prior-year quarter, reflecting an operational decrease of $484 million, or 3%, and a favorable impact of foreign exchange of $278 million. The operational decrease was primarily driven by a year-over-year decline in COVID-19 product revenues, partially offset by an increase in revenues for Abrysvo, Oncology biosimilars, Eliquis, the Prevnar family, the Vyndaqel family, and several other products across categories. Excluding contributions from Comirnaty and Paxlovid, revenues for the fourth quarter grew 9% operationally.
Fourth-quarter 2025 operational revenue reflected higher revenues primarily for:
more than offset primarily by lower revenues for:
GAAP Reported(2)Statement of Operations Highlights
SELECTED REPORTED(2)COSTS AND EXPENSES
| ($ in millions) | Fourth-Quarter | Full-Year | ||||||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | % Change | |||||||||||||||||
| Total | Oper. | Total | Oper. | |||||||||||||||||||
| Cost of Sales(2) | $ | 5,272 | $ | 5,909 | (11 | %) | (14 | %) | $ | 16,067 | $ | 17,851 | (10 | %) | (12 | %) | ||||||
| Percent of Revenues | 30.0 | % | 33.3 | % | N/A | N/A | 25.7 | % | 28.1 | % | N/A | N/A | ||||||||||
| SI&A Expenses(2) | 4,162 | 4,274 | (3 | %) | (3 | %) | 13,794 | 14,730 | (6 | %) | (7 | %) | ||||||||||
| R&D Expenses(2) | 3,206 | 3,035 | 6 | % | 5 | % | 10,437 | 10,822 | (4 | %) | (4 | %) | ||||||||||
| Acquired IPR&D Expenses(2) | 212 | 88 | * | * | 1,613 | 108 | * | * | ||||||||||||||
| Other (Income)/Deductions—net(2) | 4,514 | 2,358 | 91 | % | 94 | % | 6,724 | 4,388 | 53 | % | 55 | % | ||||||||||
| Effective Tax Rate on Reported(2)Income/(Loss) | 0.1 | % | * | (3.5 | %) | (0.4 | %) | |||||||||||||||
| * Indicates calculation not meaningful or results are greater than 100%. |
Fourth-quarter 2025 Cost of Sales(2)as a percentage of revenues decreased by 3.2 percentage points compared to the prior-year quarter, primarily driven by (i) a favorable change in sales mix including lower sales of Comirnaty, and (ii) lower amortization from the step-up of acquired inventory; partially offset by (iii) an unfavorable impact of foreign exchange and (iv) a lower favorable revision of our estimate of accrued royalties in the fourth quarter of 2025 compared to the prior-year quarter.
Fourth-quarter 2025 SI&A Expenses(2)decreased 3% operationally compared to the prior-year quarter, primarily reflecting focused investments and ongoing productivity improvements that drove a decrease in marketing and promotional spend for various products and lower spending in corporate enabling functions, partially offset by an increase in liabilities payable to participants of our supplemental savings plan.
Fourth-quarter 2025 R&D Expenses(2)increased 5% operationally compared to the prior-year quarter, driven primarily by an increase in spending in oncology and obesity product candidates, partially offset by a net decrease in spending due to pipeline focus and optimization including the expansion of our digital capabilities.
Fourth-quarter 2025 Acquired In-Process R&D Expenses(2)increased $124 million compared to the prior-year quarter, driven primarily by a $150 million charge related to an in-licensing agreement with YaoPharma.
The unfavorable period-over-period change in Other (income)/deductions—net(2)of $2.2 billion for the fourth quarter of 2025, compared to the prior-year quarter, was driven primarily by (i) higher intangible asset impairment charges in the fourth quarter of 2025, (ii) lower net gains on equity securities and (iii) the non-recurrence of gains on the partial sale of our previous investment in Haleon plc (Haleon) equity in the fourth quarter of 2024; partially offset by (iv) net periodic benefit credits associated with pension and postretirement plans incurred in the fourth quarter of 2025 versus net periodic benefit costs incurred in the fourth quarter of 2024. Included in Other (income)/deductions—net(2)are total non-cash intangible asset impairment charges of $4.4 billion that were taken in the fourth quarter of 2025 due to changes in development plans and updated long-range commercial forecasts.
Pfizer’s effective tax rate on Reported(2)loss for the fourth quarter of 2025 reflects the jurisdictional mix of earnings as well as resolutions with tax authorities.
Adjusted(3)Statement of Operations Highlights
SELECTED ADJUSTED(3)COSTS AND EXPENSES
| ($ in millions) | Fourth-Quarter | Full-Year | ||||||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | % Change | |||||||||||||||||
| Total | Oper. | Total | Oper. | |||||||||||||||||||
| Adjusted(3)Cost of Sales | $ | 5,066 | $ | 5,742 | (12 | %) | (15 | %) | $ | 15,141 | $ | 16,420 | (8 | %) | (9 | %) | ||||||
| Percent of Revenues | 28.9 | % | 32.3 | % | N/A | N/A | 24.2 | % | 25.8 | % | N/A | N/A | ||||||||||
| Adjusted(3)SI&A Expenses | 4,080 | 4,275 | (5 | %) | (5 | %) | 13,642 | 14,617 | (7 | %) | (7 | %) | ||||||||||
| Adjusted(3)R&D Expenses | 3,116 | 2,986 | 4 | % | 4 | % | 10,212 | 10,694 | (5 | %) | (5 | %) | ||||||||||
| Acquired IPR&D Expenses(3) | 212 | 88 | * | * | 1,613 | 108 | * | * | ||||||||||||||
| Adjusted(3)Other (Income)/Deductions—net | 139 | 234 | (41 | %) | (16 | %) | 827 | 1,031 | (20 | %) | (11 | %) | ||||||||||
| Effective Tax Rate on Adjusted(3)Income | 23.3 | % | 18.9 | % | 12.7 | % | 14.5 | % | ||||||||||||||
| * Indicates calculation not meaningful or results are greater than 100%. |
See the reconciliations of certain Reported(2)to non-GAAP Adjusted(3)financial measures and associated footnotes in the financial tables section of this press release located at the hyperlink below.
FULL-YEAR REVENUE SUMMARY (Full-Year 2025 vs. Full-Year 2024)
Full-year 2025 revenues totaled $62.6 billion, a decrease of $1.0 billion, or 2%, compared to full-year 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million. Excluding contributions from Comirnaty and Paxlovid, revenues for the full-year grew 6% operationally.
The operational decrease was primarily driven by a year-over-year decline in COVID-19 product revenues largely due to lower infection rates impacting Paxlovid demand as well as a narrower vaccine recommendation for COVID-19 in the U.S. impacting Comirnaty sales; partially offset by growth contributions led by the Vyndaqel family, Eliquis, Padcev, Lorbrena, Abrysvo, and Oncology biosimilars.
RECENT NOTABLE DEVELOPMENTS (Since November 4, 2025)
Product Developments
| Product/Project | Milestone | Recent Development | Link |
| Braftovi(encorafenib) | Phase 3 Results | January 2026.Announced positive results from Cohort 3, a separate, investigational randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with aBRAF V600Emutation. At the time of analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR), as assessed by BICR, compared to patients receiving standard-of-care treatment FOLFIRI with or without bevacizumab (64.4% vs 39.2%, odds ratio =2.76, p=0.001). The safety profile of Braftovi in combination with cetuximab and FOLFIRI was consistent with the known safety profile of each respective agent. | Full Release |
| Hympavzi (marstacimab) | Phase 3 Results | December 2025.Announced detailed results from the Phase 3 BASIS study (NCT03938792) evaluating Hympavzi for adults and adolescents living with hemophilia A or B with inhibitors that demonstrated the superiority of investigational use of Hympavzi in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. | Full Release |
| Padcev (enfortumab vedotin) | Phase 3 Results | December 2025.Pfizer and Astellas Pharma Inc. (Astellas) announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for Padcev in combination with pembrolizumab. The pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) versus standard of care neoadjuvant chemotherapy (gemcitabine and cisplatin) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial met its primary endpoint, demonstrating clinically meaningful and statistically significant improvements in event-free survival (EFS), and overall survival (OS), a key secondary endpoint. An additional secondary endpoint of pathologic complete response (pCR) rate for neoadjuvant Padcev plus pembrolizumab versus neoadjuvant chemotherapy was also met, and a clinically meaningful and statistically significant improvement was observed. The safety profile for Padcev plus pembrolizumab was consistent with the known profile of the treatment regimen. | Full Release |
| Regulatory | December 2025.Astellas announced the European Medicines Agency (EMA) validated for review a Type II variation application for Padcev in combination with pembrolizumab, as neoadjuvant treatment (before surgery), and then continued after radical cystectomy (surgery) as adjuvant treatment (after surgery), for adults with MIBC who are ineligible for cisplatin-containing chemotherapy. The EMA’s Committee for Medicinal Products for Human Use and subsequently the European Commission are expected to share their opinion and decision in 2026. | Full Release | |
| Regulatory | November 2025.Pfizer and Astellas announced the U.S. Food and Drug Administration (FDA) approved Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy (surgery) as adjuvant treatment for adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy. The approval of this perioperative (before and after surgery) treatment was based on results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). | Full Release | |
| Tukysa (tucatinib) | Phase 3 Results | December 2025.Announced detailed results from the Phase 3 HER2CLIMB-05 trial of Tukysa as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death among patients treated with Tukysa, trastuzumab, and pertuzumab compared to those treated with placebo, trastuzumab, and pertuzumab, as assessed by the investigator (hazard ratio [HR] of 0.641, 95% confidence interval (CI): 0.514-0.799; 2-sided p<0.0001). The combination demonstrated a manageable safety profile as a first-line maintenance therapy. | Full Release |
Pipeline Developments
A comprehensive update of Pfizer’s development pipeline was published today and is now available atwww.pfizer.com/science/drug-product-pipeline. It includes an overview of Pfizer’s research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.
| Product/Project | Milestone | Recent Development | Link |
| Ultra-Long-Acting GLP-1 (PF’3944 / MET-097i) | Phase 2b Results | February 2026.Announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of the fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study met its primary endpoint of statistically significant weight reduction at 28 weeks and demonstrated a competitive tolerability profile. Additionally, weight loss continued after the pre-planned switch from weekly to monthly dosing, with no plateau observed at 28 weeks. Detailed results from VESPER-3 will be presented on June 6, 2026 at the 86th Scientific Sessions of the American Diabetes Association®. | Full Release |
Corporate Developments
| Topic | Recent Development | Link |
| BusinessDevelopment | December 2025.Announced an exclusive global collaboration and in-license agreement with YaoPharma, a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management. Under the terms of the agreement, YaoPharma will complete an ongoing YP05002 Phase 1 clinical trial and granted Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide. YaoPharma received an upfront payment of $150 million and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.935 billion, as well as tiered royalties on sales, if approved. | Full Release |
| November 2025.Announced the completion of Pfizer’s acquisition of all outstanding shares of common stock of Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases, for $65.60 in cash per Metsera share, representing an enterprise value of approximately $7.0 billion. Additionally, Metsera shareholders were granted a contingent value right (CVR) of up to $20.65 per share of Metsera stock in potential additional payments tied to the achievement of three specified clinical and regulatory milestones. | Full Release | |
| ViiV Healthcare Limited | January 2026.Pfizer reached an agreement with GSK plc and Shionogi & Co., Ltd to exit its 11.7% investment in ViiV Healthcare Limited. Under the terms of the agreement, Pfizer will receive $1.875 billion in cash. Completion of the transaction is expected to occur in the first quarter of 2026, subject to certain regulatory clearances in relevant markets. | N/A |
PFIZER TO HOST CONFERENCE CALL
Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted info